Storia in 3 fonti

GSK walks away from Alector pact as immuno-neurology bet fizzles

GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline preclinical-only.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline preclinical-only.

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.